Prescient Therapeutics Ltd (ASX: PTX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Prescient Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$61.77 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.14 billion
Earnings per share
-0.007
Dividend per share
N/A
Year To Date Return
-39.29%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Prescient Therapeutics Ltd (ASX: PTX)
Latest News
Healthcare Shares
Guess which ASX biotech stock just rocketed 29% on big FDA news
PTX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Prescient Therapeutics Ltd
Prescient Therapeutics Ltd. is a biopharmaceutical company. The firm engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986 and is headquartered in South Melbourne, Australia.
PTX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Nov 2026 | $0.05 | $0.00 | 0.00% | 149,755 | $0.05 | $0.05 | $0.05 |
| 04 Nov 2026 | $0.05 | $0.00 | 0.00% | 141,578 | $0.05 | $0.05 | $0.05 |
| 03 Nov 2026 | $0.05 | $0.00 | 0.00% | 49,214 | $0.05 | $0.05 | $0.05 |
| 02 Nov 2026 | $0.05 | $0.00 | 0.00% | 240,332 | $0.05 | $0.05 | $0.05 |
| 30 Oct 2026 | $0.05 | $0.00 | 0.00% | 191,792 | $0.06 | $0.06 | $0.05 |
| 29 Oct 2026 | $0.06 | $0.00 | 0.00% | 17,580 | $0.05 | $0.06 | $0.05 |
| 28 Oct 2026 | $0.05 | $0.00 | 0.00% | 457,731 | $0.06 | $0.06 | $0.05 |
| 27 Oct 2026 | $0.05 | $0.00 | 0.00% | 271,970 | $0.05 | $0.05 | $0.05 |
| 26 Oct 2026 | $0.05 | $0.00 | 0.00% | 1,589,874 | $0.05 | $0.05 | $0.05 |
| 23 Oct 2026 | $0.05 | $0.00 | 0.00% | 886,759 | $0.05 | $0.06 | $0.05 |
| 22 Oct 2026 | $0.06 | $0.00 | 0.00% | 312,032 | $0.06 | $0.06 | $0.06 |
| 21 Oct 2026 | $0.06 | $0.00 | 0.00% | 439,461 | $0.06 | $0.06 | $0.06 |
| 20 Oct 2026 | $0.06 | $0.00 | 0.00% | 189,701 | $0.06 | $0.06 | $0.06 |
| 19 Oct 2026 | $0.06 | $0.00 | 0.00% | 350,151 | $0.06 | $0.06 | $0.05 |
| 16 Oct 2026 | $0.06 | $0.00 | 0.00% | 1,086,998 | $0.06 | $0.06 | $0.06 |
| 15 Oct 2026 | $0.06 | $0.00 | 0.00% | 1,116,075 | $0.07 | $0.07 | $0.06 |
| 14 Oct 2026 | $0.07 | $0.00 | 0.00% | 350,979 | $0.06 | $0.07 | $0.06 |
| 13 Oct 2026 | $0.07 | $0.00 | 0.00% | 233,555 | $0.07 | $0.07 | $0.06 |
| 12 Oct 2026 | $0.06 | $0.00 | 0.00% | 32,637 | $0.07 | $0.07 | $0.06 |
| 09 Oct 2026 | $0.07 | $0.00 | 0.00% | 736,346 | $0.07 | $0.07 | $0.06 |
| 08 Oct 2026 | $0.07 | $0.00 | 0.00% | 501,512 | $0.07 | $0.07 | $0.06 |
| 07 Oct 2026 | $0.07 | $0.00 | 0.00% | 536,706 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 30 Sep 2026 | Melanie Farris | Buy | 76,923 | $4,999 |
Participation in share purchase plan.
|
| 30 Sep 2026 | James Campbell | Buy | 153,846 | $9,999 |
Participation in share purchase plan.
|
| 30 Sep 2026 | Gavin Shepherd | Buy | 200,000 | $13,000 |
Participation in share purchase plan.
|
| 18 Nov 2025 | James Campbell | Issued | 5,257,573 | $252,363 |
Issue of options.
|
| 18 Nov 2025 | Melanie Farris | Issued | 2,628,787 | $126,181 |
Issue of options.
|
| 18 Nov 2025 | Allen Ebens | Issued | 2,628,787 | $126,181 |
Issue of options.
|
| 18 Nov 2025 | Ellen Feigal | Issued | 1,213,787 | $58,261 |
Issue of options.
|
| 18 Nov 2025 | Gavin Shepherd | Issued | 1,213,787 | $58,261 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr James Campbell | Non-Executive DirectorNon-Executive Chairman | Nov 2014 |
Dr Campbell has more than 25 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple Australian and international biotechnology companies. He was foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations. He is a member of Risk and Governance Committee.
|
| Ms Melanie Farris | Non-Executive Director | Apr 2025 |
Ms Farris is an experienced non-executive director and senior executive specialising in corporate affairs, governance, risk management, and strategic stakeholder engagement. He is the chairperson of the Risk and Governance Committee.
|
| Dr Allen James Ebens | Non-Executive Director | Jun 2020 |
Dr Ebens was formerly head of Research at Vera Therapeutics, a San Francisco based, clinical stage biotechnology company. He was recruit to Juno Therapeutics. He held senior executive positions at global pharma and biotechnology leaders Genentech and Exelixis, where he worked from concept to clinic across multiple therapeutic platforms including targeted smallmolecule therapies, antibodies, antibody-drug conjugates, and T cell recruiting antibodies. He is a member of the Risk Committee.
|
| Dr Ellen Gwen Feigal | Non-Executive Director | May 2023 |
Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC. She was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine. She is a member of the Governance Committee.
|
| Dr Gavin James Shepherd | Non-Executive Director | Jul 2024 |
Dr Shepherd has more than 25 years of experience in medicine. Dr Shepherd combines his medical expertise with business acumen. He contributes to the healthcare industry through involvement with the Medical Device Partnering Program at Flinders University and lecturing for the Royal Australian College of General Practitioners registrar training program in South Australia. He is a member of the Risk and Governance Committee.
|
| Mr Tony Di Pietro | Joint Company Secretary | Oct 2026 |
-
|
| Mr James McDonnell | Chief Executive Officer | Jan 2025 |
-
|
| Ms Mariia Skorikova | Joint Company Secretary | Oct 2026 |
-
|
| James McDonnell | Chief Executive Officer |
-
|
|
| Rebecca Tunstall | COO |
-
|
|
| Mariia Skorikova | Joint Company Secretary |
-
|
|
| Tony Di Pietro | Joint Company Secretary |
-
|
|
| Marissa Lim | Other Corporate Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| JEKL Holdings Pty Ltd (Kittel Property A/C) | 28,000,000 | 2.66% |
| Mr David Kenley | 20,675,000 | 1.97% |
| BNP Paribas Nominees Pty Ltd | 15,172,147 | 1.44% |
| BNP Paribas Noms Pty Ltd | 13,954,998 | 1.33% |
| Citicorp Nominees Pty Limited | 13,454,468 | 1.28% |
| JEKL Super Pty Ltd (Kittel Fam Sf A/C) | 13,000,000 | 1.24% |
| Dr Gavin James Shepherd & Mrs Catherine Shepherd (TPJ Superannuation Fund A/C) | 10,500,000 | 1.00% |
| Buprestid Pty Ltd (Hanlon Family S/F A/C) | 10,000,000 | 0.95% |
| SB Investments Pty Ltd (Broadley Unit A/C) | 10,000,000 | 0.95% |
| Mr Andrew Morrison Stewart | 9,506,176 | 0.90% |
| Mr Clinton Craig Hopper | 8,882,528 | 0.84% |
| Netwealth Investments Limited (Super Services A/C) | 8,839,567 | 0.84% |
| Mr Richard Thomas Hayward Daly & Mrs Sarah Kay Daly (The Daly Family Super A/C) | 7,750,000 | 0.74% |
| Mr Lee Arthur Farrington & Mrs Dian Elizabeth Farrington (Ladefarr Super Fund A/C) | 7,150,000 | 0.68% |
| Gavncath Pty Ltd (Shepherd Investment A/C) | 7,000,000 | 0.67% |
| Hsbc Custody Nominees (Australia) Limited | 6,559,591 | 0.62% |
| Mr Adrian Clement Sloman | 6,254,285 | 0.59% |
| Mr Joshua Jake O'Neile | 6,123,919 | 0.58% |
| Mr Jakov Kulis | 6,000,000 | 0.57% |
| Boycecorp Pty Ltd (Boycecorp Discretionary A/C) | 5,809,400 | 0.55% |
| SCEC Investments Pty Ltd | 5,670,726 | 0.54% |
